The inv(16) is one of the most frequent chromosomal rearrangements associated with acute myeloid leukemia. In biological and in vitro assays, the inv(16) fusion protein blocks transcription of AML-1/CBFbeta- regulated genes. In preliminary studies, the applicant demonstrated that the inv(16) fusion protein cooperates with AML-1 to repress transcription. This cooperativity requires the ability of the translocation fusion protein to bind to AML-1. Mutational analysis and cell fractionation experiments indicate that the inv(16) fusion protein acts in the nucleus and that repression occurs when the complex is bound to DNA. He also found that the inv(16) fusion protein binds to AML-1 when it is associated with the mSin3A corepressor. An AML-1 mutant that fails to bind mSin3A was impaired in cooperative repression, suggesting that the inv(16) fusion protein acts through mSin3 and possibly other corepressors. Finally, he demonstrated that the C-terminal portion of the inv(16) fusion protein contains a repression domain. He hypothesizes that the fusion of CBFbeta with the smooth muscle myosin heavy chain gene MYH11 creates a transcriptional corepressor for AML-1B that promotes leukemogenesis by repressing the p21Waf1/Cip1 cyclin dependent kinase inhibitor and the p14ARF and neurofibromin tumor suppressor genes. He will define the molecular mechanism of transcriptional repression by the inv(16) fusion protein, and determine if p21Waf1/Cip1, p14ARF and Nf1 are direct targets for regulation by the inv(16) fusion protein. In addition, he will determine the contribution of these putative inv(16)-regulated genes to leukemogenesis by creating mice lacking p21Waf1/Cip1, p14ARF and Nf1. By determining the mechanism of inv(16)-mediated repression and identifying critical target genes for regulation, he will begin to elucidate the molecular mechanism of inv(16)-mediated leukemogenesis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA087549-02
Application #
6378044
Study Section
Pathology B Study Section (PTHB)
Project Start
2000-06-01
Project End
2005-05-31
Budget Start
2001-06-01
Budget End
2002-05-31
Support Year
2
Fiscal Year
2001
Total Cost
$272,700
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Biochemistry
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Kim, H-G; LeGrand, J; Swindle, C S et al. (2017) The assembly competence domain is essential for inv(16)-associated acute myeloid leukemia. Leukemia 31:2267-2271
Ko, Rose M; Kim, Hyung-Gyoon; Wolff, Linda et al. (2008) Roles of p15Ink4b and p16Ink4a in myeloid differentiation and RUNX1-ETO-associated acute myeloid leukemia. Leuk Res 32:1101-11
Amann, Joseph M; Chyla, Brenda J Irvin; Ellis, Tiffany C et al. (2005) Mtgr1 is a transcriptional corepressor that is required for maintenance of the secretory cell lineage in the small intestine. Mol Cell Biol 25:9576-85
Moreno-Miralles, Isabel; Pan, Ling; Keates-Baleeiro, Jennifer et al. (2005) The inv(16) cooperates with ARF haploinsufficiency to induce acute myeloid leukemia. J Biol Chem 280:40097-103
Yang, Genyan; Khalaf, Waleed; van de Locht, Louis et al. (2005) Transcriptional repression of the Neurofibromatosis-1 tumor suppressor by the t(8;21) fusion protein. Mol Cell Biol 25:5869-79
Linggi, Bryan E; Brandt, Stephen J; Sun, Zu-Wen et al. (2005) Translating the histone code into leukemia. J Cell Biochem 96:938-50
Durst, Kristie L; Lutterbach, Bart; Kummalue, Tanawan et al. (2003) The inv(16) fusion protein associates with corepressors via a smooth muscle myosin heavy-chain domain. Mol Cell Biol 23:607-19
Wood, Lauren D; Irvin, Brenda J; Nucifora, Giuseppina et al. (2003) Small ubiquitin-like modifier conjugation regulates nuclear export of TEL, a putative tumor suppressor. Proc Natl Acad Sci U S A 100:3257-62
Hiebert, Scott W; Reed-Inderbitzin, Edward F; Amann, Joseph et al. (2003) The t(8;21) fusion protein contacts co-repressors and histone deacetylases to repress the transcription of the p14ARF tumor suppressor. Blood Cells Mol Dis 30:177-83
Irvin, Brenda J; Wood, Lauren D; Wang, Lilin et al. (2003) TEL, a putative tumor suppressor, induces apoptosis and represses transcription of Bcl-XL. J Biol Chem 278:46378-86

Showing the most recent 10 out of 11 publications